Drug Trial Radar · NCT07645235
A Study to Evaluate Gepotidacin Exposure in Breast Milk of Healthy Lactating Women
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
8
Planned (sponsor's estimate)
Start
Jul 23, 2026
Primary completion
May 17, 2027
Study completion May 17, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Biomedical Advanced Research and Development Authority
- First posted
- Jun 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to evaluate the pharmacokinetic of gepotidacin in fed healthy lactating women.
Conditions
- Urinary Tract Infections
Interventions
GepotidacinDrug
A single oral dose of 3000 mg gepotidacin will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration-time curve from time zero to the last measurable concentration time point (t) (AUC[0 to t]) of gepotidacin in breast milkTime frame: Up to 48 hours post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Las Vegas, Nevada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.